Abstract: The present invention relates to a novel printable boron doping paste in the form of a hybrid gel based on precursors of inorganic oxides, preferably of silicon dioxide, aluminium oxide and boron oxide, in the presence of organic polymer particles, where the pastes according to the invention can be used in a simplified process for the production of solar cells, where the hybrid gel according to the invention functions both as doping medium and as diffusion barrier.
Type:
Application
Filed:
March 24, 2016
Publication date:
May 3, 2018
Applicant:
MERCK PATENT GMBH
Inventors:
Oliver DOLL, Ingo KOEHLER, Sebastian BARTH
Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
Type:
Application
Filed:
December 17, 2015
Publication date:
May 3, 2018
Applicant:
MERCK SHARP & DOHME CORP.
Inventors:
JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JIAQIANG CAI, SHILAN LIU, DAHAI WANG, HAO WU, CHUNDAO YANG
Abstract: The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
May 1, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Matthew Lloyd Childers, Peter Fuller, David Guerin, Jason David Katz, Qinglin Pu, Mark E. Scott, Christopher F. Thompson, Michelle Martinez, Danielle Falcone, Luis Torres, Yongqi Deng, Ravi Kurukulasuriya, Hongbo Zeng, Yunfeng Bai, Norman Kong, Yumei Liu, Zhixiang Zheng
Abstract: A dispenser for opening a tape like packaging comprising first and second films releasably connected to each other, forming envelopes sealed around an object, and disposed sequentially with a predetermined pitch. The dispenser comprises a space for holding a container of the packaging, a separator through which the packaging can be passed, for spreading apart and separating the films at an outlet thereof when a pulling force is acting on said first and second films, thereby opening envelopes and releasing the objects contained therein, and means for winding up separated first and second films of the tape like packaging. The separator further comprises a cover member that is articulated to the dispenser to be movable between a closed position and an open position.
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Type:
Grant
Filed:
December 1, 2014
Date of Patent:
May 1, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Thomas Bara, Harry R. Chobanian, Yan Guo, Hubert Josien, Michael Miller, Barbara Pio, Christopher W. Plummer, Cangming Yang, Dong Xiao
Abstract: In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1A, R1B, R2A, R2B, R2, R3, RN, ring A, RA, m, ring B, RB, and n are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
Abstract: Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
May 1, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Christopher Dinsmore, Peter Fuller, David Guerin, Christopher F. Thompson, Qinglin Pu, Mark E. Scott, Jason David Katz, Ravi Kurukulasuriya, Joshua T. Close, Danielle Falcone, Jason Brubaker, Hongbo Zeng, Yunfeng Bai, Jianmin Fu, Norman Kong, Yumei Liu, Zhixiang Zheng
Abstract: Insulin conjugates comprising an insulin analog molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
Type:
Application
Filed:
April 4, 2016
Publication date:
April 26, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Danqing Feng, Erin N. Guidry, Pei Huo, Niels C. Kaarsholm, Songnian Lin, Ravi P. Nargund, Lin Yan
Abstract: The present invention is directed to process for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.
Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
Type:
Application
Filed:
March 24, 2016
Publication date:
April 26, 2018
Applicant:
Merck Sharp & Dohme Corp
Inventors:
Jason M. COX, Lijun MA, Xiaoyan ZHOU, Robin E. HAIMBACH, Paul J. COLEMAN, Haihong ZHOU, David E. KELLEY, Selwyn Aubrey STOCH, Le T. DUONG, Maarten HOEK
Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
Type:
Application
Filed:
November 13, 2017
Publication date:
April 26, 2018
Applicant:
Merck Sharp & Dohme B.V.
Inventors:
Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
Abstract: The invention relates to compounds of the formula I, to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, L1, L2, L3 and L4 have the meanings indicated herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PM-VA, PALC, IPS, PS-IPS, SA-VA, SS-VA, FFS or PS-FFS effect.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
April 24, 2018
Assignee:
MERCK PATENT GMBH
Inventors:
Harald Hirschmann, Monika Bauer, Martina Windhorst, Marcus Reuter, Volker Reiffenrath, Matthias Bremer
Abstract: The invention generally relates to formulations for use in organic semiconductor layers of organic electronic devices, and more specifically in organic field effect transistors, to organic semiconductor layers prepared from such formulations, and to organic electronic devices and organic field effect transistors encompassing such organic semiconductor layers.
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Type:
Grant
Filed:
October 27, 2014
Date of Patent:
April 24, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Alexander Pasternak, Haifeng Tang, Jessica Frie, Ronald Dale Ferguson, Zhiqiang Guo, Zhi-Cai Shi, Brian Cato, Qinghong Fu
Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
Type:
Grant
Filed:
June 9, 2014
Date of Patent:
April 24, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Mark W. Embrey, Kerim Babaoglu, Abbas Walji, John S. Wai, Paul J. Coleman
Abstract: A medication injector that has an alert indicator that alerts the user when the medication injector is approaching near the end of its medication supply is disclosed. The alert indicator gives the user an opportunity to make preparations to obtain additional medication for the injector if there is an insufficient amount of medication in the injector to enable the user to dispense the required dosage amount with the next injection. Initially, the alert indicator is not visible to the user, but becomes visible to the user when the injector is near empty.
Type:
Grant
Filed:
December 5, 2013
Date of Patent:
April 24, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Peter A. Basile, Jeffrey C. Givand, Steven Carl Persak
Abstract: A containment and transfer device for use with highly active or sensitive compounds, comprising a sleeve or a bag with one or more flexible walls, a first sanitary clamp, an endcap, a second sanitary clamp and a compression clamp. The sleeve or bag has a first end for connection to a container, and a second end for (a) connection to a storage or mixing vessel at the discharge location, or (b) connection to an endcap for transportation. The flexible walls surround and define an internal passageway in that permits compounds in the first end of the sleeve or bag to pass into the second end of the sleeve or bag. The compression clamp compresses the flexible walls of the sleeve or bag together to produce a barrier across the internal passageway, preventing the highly active or sensitive compound from flowing into the second end of the sleeve or bag during packing, transporting and discharging the device.
Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
Type:
Application
Filed:
December 18, 2017
Publication date:
April 19, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Joseph TERRACCIANO, Nicole Miller DAMOUR, Chun JIANG, Giovanni FOGLIATO, Giuseppe Alessandron DONADELLI, Dario RESEMINI
Abstract: The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I): which are tropomyos-in-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
Type:
Application
Filed:
April 4, 2016
Publication date:
April 19, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Craig A. Stump, Yi Heng Chen, Ping Liu, Dongfang Meng, Jane Yang Wu, Chun Sing Li, Zhiqi Qi
Abstract: Liquid-crystalline media are disclosed containing one or more compounds of formula I along with components containing these media for high-frequency technology, in particular phase shifters and microwave array antennas.